Discussion on an anti CD47 drug and its lack of responses, potential differences in agents, and the need for further data and trials

Acute myeloid leukemia (AML) has seen rapid progression in the field of immuno-oncology which has led to vast improvements in patient outcomes. The annual Society of Hematological Oncology (SOHO) allowed for discussions on the translation of key data into clinical practice, including the state of the art in immunotherapy for AML.

In this podcast, Marion Subklewe of LMU Hospital Munich, Munich, Germany, leads a panel discussion evaluating checkpoint inhibitors, anti-CD47 therapy, BiTEs, and CAR T-cell approaches in AML alongside Naval Daver of the University of Texas MD Anderson Center, Houston, TX, David Sallman of H. Lee Moffit Cancer Center, Tampa, FL and Amer Zeidan of Yale University and Yale Cancer Center, New Haven, CT.

The post The AML Sessions: Immunotherapy appeared first on VJHemOnc.